BIODEL INC. (BIOD)

Biodel, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of treatments for endocrine disorders, such as diabetes and osteoporosis. The company develops its product candidates by utilizing its proprietary VIAdel technology. It has two insulin product candidates in clinical trials for the treatment of diabetes, including VIAject and VIAtab. VIAject is an injectable formulation of recombinant human insulin, which is in pivotal Phase III clinical trials in patients with Type 1 and Type 2 diabetes. VIAtab is a sublingual tablet formulation of insulin, which is in Phase I clinical trial in patients with diabetes. The company also has two preclinical product candidates for the treatment of osteoporosis comprising VIAmass, a sublingual formulation of parathyroid hormone 1-34; and VIAcaltm, a sublingual formulation of salmon calcitonin. Biodel was founded in 2003 and is based in Danbury, Connecticut.